A monoclonal antibody that acts as a thyroid stimulating hormone receptor (TSHR) antagonist is in early clinical development for the treatment of patients with Graves’ disease or thyroid cancer. Grave’s disease is an autoimmune disease that leads to a generalized overactivity of the entire thyroid gland (hyperthyroidism).